|
EP1941908B1
(en)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for heart disease
|
|
WO2007116962A1
(ja)
|
2006-04-07 |
2007-10-18 |
Osaka University |
筋再生促進剤
|
|
SI2374818T1
(sl)
|
2006-06-02 |
2013-03-29 |
Regeneron Pharmaceuticals, Inc. |
Visokoafinitetna protitelesa za humani IL-6 receptor
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
EP2057191A1
(en)
|
2006-08-18 |
2009-05-13 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
|
WO2008071685A1
(en)
*
|
2006-12-13 |
2008-06-19 |
Ablynx N.V. |
Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
|
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
RU2450829C2
(ru)
|
2007-01-23 |
2012-05-20 |
Синсу Юниверсити |
Ингибитор хронического отторжения
|
|
MX2009013328A
(es)
|
2007-06-25 |
2010-06-02 |
Esbatech An Alcon Biomedical R |
Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
|
|
WO2009010539A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Ablynx. N.V. |
Receptor for interleukin-6 (il-6) from macaca fascicularis
|
|
WO2009095489A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
|
US20110091462A1
(en)
*
|
2008-03-05 |
2011-04-21 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
|
|
CN102112155B
(zh)
|
2008-06-05 |
2016-08-10 |
埃博灵克斯股份有限公司 |
针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
|
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
US9034325B2
(en)
|
2008-07-22 |
2015-05-19 |
Ablynx N.V. |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
CA2740561C
(en)
|
2008-10-14 |
2021-01-19 |
National Research Council Of Canada |
Bsa-specific antibodies
|
|
JP5823871B2
(ja)
*
|
2008-12-10 |
2015-11-25 |
アブリンクス エン．ヴェー． |
血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
|
EP2370465B1
(en)
|
2008-12-19 |
2019-01-23 |
Ablynx N.V. |
Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
|
|
US20110311515A1
(en)
|
2009-01-14 |
2011-12-22 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
AU2010208637A1
(en)
*
|
2009-01-29 |
2011-08-04 |
Abbvie Inc. |
IL-1 binding proteins
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
JP4809930B2
(ja)
|
2009-03-19 |
2011-11-09 |
中外製薬株式会社 |
関節リウマチ治療剤
|
|
SG174862A1
(en)
|
2009-04-10 |
2011-11-28 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
|
|
US10618964B2
(en)
|
2009-04-10 |
2020-04-14 |
Ablynx N.V. |
Nanobody against IL-6R
|
|
US9464138B2
(en)
|
2009-04-30 |
2016-10-11 |
Ablynx N.V. |
Method for the production of domain antibodies
|
|
SMT201700376T1
(it)
|
2009-06-05 |
2017-09-07 |
Ablynx Nv |
Costrutti trivalenti di nanobody anti-virus respiratorio sinciziale umano (hrsv) per la prevenzione e/o il trattamento di infezioni del tratto respiratorio
|
|
ES2804450T3
(es)
|
2009-07-10 |
2021-02-08 |
Ablynx Nv |
Método para la producción de dominios variables
|
|
ES3050913T3
(en)
|
2009-09-03 |
2025-12-29 |
Ablynx Nv |
Stable formulations of polypeptides and uses thereof
|
|
US20120283415A1
(en)
|
2009-09-10 |
2012-11-08 |
Ucb Pharma S.A. |
Multivalent Antibodies
|
|
UY32917A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moléculas de unión a dll-4
|
|
US20110172398A1
(en)
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
|
EP2486056A1
(en)
|
2009-10-09 |
2012-08-15 |
Ablynx N.V. |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
WO2011067160A1
(en)
|
2009-12-01 |
2011-06-09 |
Ablynx Nv |
Von willebrand factor specific binding agents and uses thereof
|
|
EP3309176B1
(en)
|
2009-12-14 |
2025-10-01 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
WO2011095545A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx Nv |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
|
PT2533761T
(pt)
|
2010-02-11 |
2019-06-17 |
Ablynx Nv |
Métodos e composições para a preparação de aerossóis
|
|
JP5826194B2
(ja)
|
2010-03-03 |
2015-12-02 |
アブリンクス ナームローゼ フェンノートシャップ |
二パラトープ性ａ−ベータ結合ポリペプチド
|
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
SG185354A1
(en)
|
2010-05-20 |
2012-12-28 |
Ablynx Nv |
Biological materials related to her3
|
|
PL2578231T3
(pl)
|
2010-05-28 |
2023-01-16 |
Chugai Seiyaku Kabushiki Kaisha |
Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
|
|
EP2582811B1
(en)
*
|
2010-06-17 |
2019-09-18 |
VIB vzw |
Increased protein expression through increased membrane formation
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
CU24111B1
(es)
|
2010-11-08 |
2015-08-27 |
Novartis Ag |
Polipéptidos que se enlazan a cxcr2
|
|
JP6181040B2
(ja)
*
|
2011-03-28 |
2017-08-16 |
アブリンクス エン．ヴェー． |
二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
EP2707382B1
(en)
|
2011-05-09 |
2019-07-17 |
Ablynx NV |
Method for the production of immunoglobulin single variable domains
|
|
US9505840B2
(en)
|
2011-05-27 |
2016-11-29 |
Ablynx N.V. |
Inhibition of bone resorption with RANKL binding peptides
|
|
US9695227B2
(en)
|
2011-06-21 |
2017-07-04 |
Vrije Universiteit Brussel |
Binding domains directed against GPCR:G protein complexes and uses derived thereof
|
|
KR101965462B1
(ko)
|
2011-06-23 |
2019-04-04 |
아블린쓰 엔.브이. |
면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
|
|
PT2723771T
(pt)
|
2011-06-23 |
2019-12-11 |
Ablynx Nv |
Proteínas de ligação à albumina sérica
|
|
EP4350345A3
(en)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
|
EP2974737B1
(en)
|
2011-06-23 |
2025-10-22 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
|
|
ES2813432T3
(es)
|
2011-08-17 |
2021-03-23 |
Glaxo Group Ltd |
Proteínas y péptidos modificados
|
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
|
CN103889451B
(zh)
|
2011-09-30 |
2016-06-29 |
埃博灵克斯股份有限公司 |
与C-Met相关的生物物质
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
|
AU2013226340B2
(en)
|
2012-02-27 |
2017-06-22 |
Ablynx N.V. |
CX3CR1-binding polypeptides
|
|
NZ628584A
(en)
|
2012-03-30 |
2016-04-29 |
Boehringer Ingelheim Int |
Ang2-binding molecules
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
ES2715279T3
(es)
|
2012-05-24 |
2019-06-03 |
Vib Vzw |
Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
AU2014214054B2
(en)
|
2013-02-05 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
NO2951201T3
(enExample)
|
2013-02-08 |
2018-03-17 |
|
|
|
WO2014140376A1
(en)
|
2013-03-15 |
2014-09-18 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
|
EP3027642B1
(en)
*
|
2013-07-31 |
2020-08-19 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
|
JP6556153B2
(ja)
|
2013-11-04 |
2019-08-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
合成単一ドメイン抗体
|
|
EP2873680A1
(en)
*
|
2013-11-13 |
2015-05-20 |
F.Hoffmann-La Roche Ag |
Oligopeptide and methods for producing conjugates thereof
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US20160326220A1
(en)
|
2013-12-24 |
2016-11-10 |
Vib Vzw |
Secretion and functional display of chimeric polypeptides
|
|
AU2015217846B2
(en)
|
2014-01-30 |
2019-10-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opioid receptor binding agents and uses thereof
|
|
IL318433A
(en)
|
2014-05-16 |
2025-03-01 |
Ablynx Nv |
Improved immunoglobulin variable complexes
|
|
AU2015261536B2
(en)
|
2014-05-16 |
2020-05-07 |
Ablynx Nv |
Improved immunoglobulin variable domains
|
|
EP3143403B1
(en)
|
2014-05-16 |
2021-10-27 |
Ablynx N.V. |
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
|
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
WO2016012363A1
(en)
|
2014-07-22 |
2016-01-28 |
Vib Vzw |
Methods to select for agents that stabilize protein complexes
|
|
CA2961774C
(en)
|
2014-10-07 |
2023-05-23 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
AU2015334984A1
(en)
|
2014-10-21 |
2017-04-13 |
Ablynx Nv |
Treatment of IL-6R related diseases
|
|
CN107406497A
(zh)
|
2014-12-19 |
2017-11-28 |
埃博灵克斯股份有限公司 |
半胱氨酸连接的纳米抗体二聚体
|
|
JP6130983B2
(ja)
|
2015-02-27 |
2017-05-17 |
中外製薬株式会社 |
Ｉｌ−６関連疾患治療用組成物
|
|
EP3271391A1
(en)
*
|
2015-03-20 |
2018-01-24 |
Ablynx N.V. |
Glycosylated immunoglobulin single variable domains
|
|
KR20170132749A
(ko)
|
2015-03-31 |
2017-12-04 |
브이에이치스퀘어드 리미티드 |
폴리펩티드
|
|
SG11201706840WA
(en)
|
2015-03-31 |
2017-09-28 |
Vhsquared Ltd |
Peptide construct having a protease-cleavable linker
|
|
EP3277316B1
(en)
|
2015-04-02 |
2025-03-05 |
Ablynx N.V. |
Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
|
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
|
|
DK3294319T3
(da)
|
2015-05-13 |
2024-07-22 |
Ablynx Nv |
T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet
|
|
WO2016180969A1
(en)
|
2015-05-13 |
2016-11-17 |
Ablynx N.V. |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
EP3299810B1
(en)
|
2015-05-19 |
2021-07-07 |
National Center of Neurology and Psychiatry |
Method for determining application of novel therapy to multiple sclerosis (ms) patient
|
|
AU2016263808B2
(en)
|
2015-05-21 |
2019-01-03 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
NO2768984T3
(enExample)
|
2015-11-12 |
2018-06-09 |
|
|
|
EP3974449A1
(en)
|
2015-11-13 |
2022-03-30 |
Ablynx NV |
Improved serum albumin-binding immunoglobulin variable domains
|
|
HK1254951A1
(zh)
|
2015-11-18 |
2019-08-02 |
Merck Sharp & Dohme Llc |
Pd1和/或lag3结合剂
|
|
JP7046804B2
(ja)
|
2015-11-18 |
2022-04-04 |
アブリンクス エン．ヴェー． |
改良された血清アルブミン結合剤
|
|
CA3003777A1
(en)
|
2015-11-18 |
2017-05-26 |
Merck Sharp & Dohme Corp. |
Pd1/ctla4 binders
|
|
TWI754622B
(zh)
|
2015-11-18 |
2022-02-11 |
美商默沙東藥廠 |
Ctla4結合劑
|
|
JP7256011B2
(ja)
|
2015-11-27 |
2023-04-11 |
アブリンクス エン．ヴェー． |
Ｃｄ４０ｌを阻害するポリペプチド
|
|
SI3383425T1
(sl)
|
2015-12-04 |
2020-11-30 |
Boehringer Ingelheim International Gmbh |
Biparatopični polipeptidi, ki antagonizirajo WNT-signaliziranje v tumorskih celicah
|
|
EP3405491A1
(en)
|
2016-01-21 |
2018-11-28 |
VHsquared Limited |
Polypeptides
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
EP3452505A1
(en)
|
2016-05-02 |
2019-03-13 |
Ablynx NV |
Treatment of rsv infection
|
|
MX2018014228A
(es)
|
2016-05-20 |
2019-08-12 |
Harpoon Therapeutics Inc |
Proteina de union de albumina sérica de dominio unico.
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
MX2018014227A
(es)
|
2016-05-20 |
2019-08-22 |
Harpoon Therapeutics Inc |
Proteinas de union de cadena unica de fragmento variable cd3.
|
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
|
WO2017220645A1
(en)
|
2016-06-23 |
2017-12-28 |
Ablynx N.V. |
Improved pharmacokinetic assays for immunoglobulin single variable domains
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
AU2017332721B2
(en)
|
2016-09-20 |
2023-11-09 |
Sara BUHRLAGE |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
|
EP3519438A1
(en)
|
2016-09-30 |
2019-08-07 |
VHsquared Limited |
Compositions
|
|
KR20240076829A
(ko)
|
2016-11-16 |
2024-05-30 |
아블린쓰 엔.브이. |
Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
AU2017364818C1
(en)
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
CN110049997B
(zh)
|
2016-12-07 |
2023-09-22 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合免疫球蛋白单可变结构域
|
|
WO2018111099A1
(en)
|
2016-12-12 |
2018-06-21 |
Stichting Vumc |
Biomarkers and treatments for cerebral amyloid angiopathy (caa)
|
|
ES2991459T3
(es)
|
2017-01-17 |
2024-12-03 |
Ablynx Nv |
Ligantes de albúmina sérica mejorados
|
|
EP3571224B1
(en)
|
2017-01-17 |
2024-08-07 |
Ablynx NV |
Improved serum albumin binders
|
|
JP7186401B2
(ja)
|
2017-02-28 |
2022-12-09 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
タンパク質の経口送達のための手段及び方法
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
EP3602056A1
(en)
|
2017-03-31 |
2020-02-05 |
Ablynx N.V. |
Improved immunogenicity assays
|
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
KR20200026810A
(ko)
|
2017-05-12 |
2020-03-11 |
하푼 테라퓨틱스, 인크. |
Msln 표적화 삼중 특이적 단백질 및 사용 방법
|
|
AR111840A1
(es)
|
2017-05-31 |
2019-08-21 |
Boehringer Ingelheim Int |
Polipéptidos que antagonizan la señalización wnt en células tumorales
|
|
US11603401B2
(en)
|
2017-06-02 |
2023-03-14 |
Ablynx N.V. |
Aggrecan binding immunoglobulins
|
|
EP3630817A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Polypeptides binding adamts5, mmp13 and aggrecan
|
|
TW202417517A
(zh)
|
2017-06-02 |
2024-05-01 |
德商麥克專利有限公司 |
與ｍｍｐ１３結合之免疫球蛋白
|
|
LT3630847T
(lt)
|
2017-06-02 |
2024-12-10 |
Merck Patent Gmbh |
Adamts surišantys imunoglobulinai
|
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
WO2019016237A1
(en)
|
2017-07-19 |
2019-01-24 |
Vib Vzw |
AGENTS FOR CONNECTING TO SERUM ALBUMIN
|
|
AU2018331725A1
(en)
|
2017-09-13 |
2020-04-23 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-6R antibody and antigen binding fragment thereof and medical use
|
|
CN107492601A
(zh)
*
|
2017-09-30 |
2017-12-19 |
京东方科技集团股份有限公司 |
一种显示器件及其封装方法、显示装置
|
|
FI3694529T3
(fi)
|
2017-10-13 |
2024-09-17 |
Harpoon Therapeutics Inc |
Trispesifiset proteiinit ja niiden käyttömenetelmät
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019078344A1
(ja)
|
2017-10-20 |
2019-04-25 |
学校法人兵庫医科大学 |
抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
|
WO2019086548A1
(en)
|
2017-10-31 |
2019-05-09 |
Vib Vzw |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
|
ES3050257T3
(en)
|
2017-11-15 |
2025-12-19 |
Novo Nordisk As |
Factor x binders enhancing fx activation
|
|
MX2020005160A
(es)
|
2017-11-28 |
2020-08-20 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a ligando que tiene actividad de union a ligando ajustable.
|
|
CA3083259A1
(en)
|
2017-11-28 |
2019-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide including antigen-binding domain and carrying section
|
|
CA3089377A1
(en)
|
2018-01-26 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss2 antibodies and antigen-binding fragments
|
|
SG11202006902QA
(en)
|
2018-02-06 |
2020-08-28 |
Ablynx Nv |
Methods of treating initial episode of ttp with immunoglobulin single variable domains
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
EP3758755A1
(en)
|
2018-02-26 |
2021-01-06 |
Ablynx N.V. |
Improved nucleotide sequences encoding peptide linkers
|
|
CA3090305A1
(en)
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
WO2019166622A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
|
MA52205A
(fr)
|
2018-04-09 |
2021-02-17 |
Amgen Inc |
Protéines de fusion du facteur de différenciation de croissance 15
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
|
CA3128212A1
(en)
|
2019-01-31 |
2020-08-06 |
Sanofi Biotechnology |
Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
|
|
EP3935084B1
(en)
|
2019-03-08 |
2024-06-12 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
BR112021021077A2
(pt)
|
2019-04-24 |
2021-12-14 |
E Zilberstein Moshe |
Métodos de diagnóstico e tratamento de artrite reumatoide
|
|
AU2020266012A1
(en)
|
2019-04-29 |
2021-11-25 |
Confo Therapeutics N.V. |
Chimeric proteins and methods to screen for compounds and ligands binding to GPCRs
|
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
WO2020221888A1
(en)
|
2019-04-30 |
2020-11-05 |
Vib Vzw |
Cystic fibrosis transmembrane conductance regulator stabilizing agents
|
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
|
US12472254B2
(en)
|
2019-05-28 |
2025-11-18 |
Vib Vzw |
CD8+ T-cells lacking plexins and their application in cancer treatment
|
|
KR20230061198A
(ko)
|
2019-06-04 |
2023-05-08 |
사노피 바이오테크놀로지 |
류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
|
|
KR20220064953A
(ko)
|
2019-06-21 |
2022-05-19 |
소리소 파마슈티컬스 인크. |
폴리펩티드
|
|
EP3986571A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
AU2020351274A1
(en)
|
2019-09-20 |
2022-05-05 |
Invectys SAS |
Single-domain antibodies directed against LILRB2
|
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
|
WO2021078786A1
(en)
|
2019-10-21 |
2021-04-29 |
Vib Vzw |
Nanodisc-specific antigen-binding chimeric proteins
|
|
EP4058477A2
(en)
|
2019-11-11 |
2022-09-21 |
IBI-AG Innovative Bio Insecticides Ltd. |
Insect control nanobodies and uses thereof
|
|
WO2021105438A1
(en)
|
2019-11-27 |
2021-06-03 |
Vib Vzw |
Positive allosteric modulators of the calcium-sensing receptor
|
|
WO2021113736A1
(en)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Single-domain antibody to chloramphenicol
|
|
JP7657797B2
(ja)
|
2019-12-06 |
2025-04-07 |
アブリンクス エン．ヴェー． |
ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
|
|
JP7719775B2
(ja)
|
2019-12-06 |
2025-08-06 |
アブリンクス エン．ヴェー． |
ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
|
|
CN114980974A
(zh)
|
2019-12-09 |
2022-08-30 |
艾伯霖克斯公司 |
含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
US20240027467A1
(en)
|
2019-12-20 |
2024-01-25 |
Vib Vzw |
Nanobody Exchange Chromatography
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
US20230075965A1
(en)
|
2020-01-24 |
2023-03-09 |
Constantine S. Mitsiades |
Uses of biomarkers for improving immunotherapy
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
KR20220140503A
(ko)
|
2020-02-10 |
2022-10-18 |
리제너론 파마슈티칼스 인코포레이티드 |
항-tmprss2 항체 및 항원 결합 단편
|
|
AU2021224851A1
(en)
|
2020-02-21 |
2022-09-15 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
WO2021170540A1
(en)
|
2020-02-25 |
2021-09-02 |
Vib Vzw |
Leucine-rich repeat kinase 2 allosteric modulators
|
|
CN115397868A
(zh)
|
2020-03-30 |
2022-11-25 |
埃博灵克斯股份有限公司 |
用于产生和纯化多价免疫球蛋白单可变域的方法
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
EP4144758A4
(en)
|
2020-04-22 |
2024-05-15 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
|
|
US20230167182A1
(en)
*
|
2020-05-18 |
2023-06-01 |
Biosion Inc. |
Antibodies binding il6r and uses thereof
|
|
CN116096745A
(zh)
|
2020-05-26 |
2023-05-09 |
瑞泽恩制药公司 |
抗sars-cov-2纤突糖蛋白抗体和抗原结合片段
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
WO2022060223A1
(en)
|
2020-09-16 |
2022-03-24 |
Linxis B.V. |
Internalizing binding molecules
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
US20230364049A1
(en)
|
2020-09-24 |
2023-11-16 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
|
IL301581A
(en)
|
2020-09-25 |
2023-05-01 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
|
|
JP2023548046A
(ja)
|
2020-10-23 |
2023-11-15 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体を使用する、補体障害を有する患者の処置方法
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
EP4255929A2
(en)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US11946055B2
(en)
*
|
2020-12-10 |
2024-04-02 |
The Regents Of The University Of California |
Protein engineering via error-prone orthogonal replication and yeast surface display
|
|
US11897951B2
(en)
|
2020-12-18 |
2024-02-13 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
|
|
KR20230123495A
(ko)
|
2020-12-18 |
2023-08-23 |
아블린쓰 엔.브이. |
글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
|
|
WO2022129637A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
US20240052044A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
|
CA3206125A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
CA3207548A1
(en)
|
2021-02-05 |
2022-08-11 |
Xavier Saelens |
Sarbecovirus binders
|
|
EP4291175A1
(en)
|
2021-02-11 |
2023-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancers using sting agonists
|
|
US20240130999A1
(en)
|
2021-02-17 |
2024-04-25 |
Vib Vzw |
Inhibition of SLC4A4 in the Treatment of Cancer
|
|
AU2022224636A1
(en)
|
2021-02-19 |
2023-09-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
|
WO2022175532A1
(en)
|
2021-02-19 |
2022-08-25 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
US12454572B2
(en)
|
2021-03-02 |
2025-10-28 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating anemia in myelodysplastic syndromes
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
US20250319183A1
(en)
|
2021-04-07 |
2025-10-16 |
David Avigan |
Compositions and methods for the treatment of cancer
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
JP2024523921A
(ja)
|
2021-06-23 |
2024-07-02 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
特異的バインダーの選択手段及び方法
|
|
JP2024527607A
(ja)
|
2021-07-14 |
2024-07-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体及び抗原結合断片
|
|
CA3228014A1
(en)
|
2021-07-30 |
2023-02-16 |
Vib Vzm |
Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
|
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
|
US20240409638A1
(en)
|
2021-10-07 |
2024-12-12 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
|
CN114085287B
(zh)
*
|
2021-11-12 |
2022-10-25 |
中国农业科学院北京畜牧兽医研究所 |
犬细小病毒纳米抗体cpv-vhh-f5及其应用
|
|
US20250011767A1
(en)
|
2021-11-18 |
2025-01-09 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
|
WO2023089191A1
(en)
|
2021-11-22 |
2023-05-25 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
|
US20250381241A1
(en)
|
2021-11-29 |
2025-12-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
TW202342508A
(zh)
|
2021-12-17 |
2023-11-01 |
比利時商艾伯霖克斯公司 |
包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
|
|
US20250304664A1
(en)
|
2022-01-12 |
2025-10-02 |
Vib Vzw |
Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
|
|
EP4476250A1
(en)
|
2022-02-07 |
2024-12-18 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
JP2025509078A
(ja)
|
2022-02-10 |
2025-04-11 |
アフィセル セラピューティクス カンパニー リミテッド |
Ｃｄ４０ｌに特異的に結合するステフィンａタンパク質変異体及びその用途
|
|
WO2023155902A1
(en)
|
2022-02-18 |
2023-08-24 |
Chongqing Mingdao Haoyue Biotechnology Co., Ltd. |
Intranasal formulations and anti-sars-cov-2-spike protein antibodies
|
|
US20250235534A1
(en)
|
2022-04-13 |
2025-07-24 |
Vib Vzw |
An LTBR Agonist In Combination Therapy Against Cancer
|
|
WO2023215498A2
(en)
*
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
JP2025517728A
(ja)
|
2022-05-18 |
2025-06-10 |
ブイアイビー ブイゼットダブリュ |
サルベコウイルスのスパイクｓ２サブユニットバインダー
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
KR20250023503A
(ko)
|
2022-06-14 |
2025-02-18 |
아블린쓰 |
T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
EP4558520A1
(en)
|
2022-07-18 |
2025-05-28 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
|
AU2023313033A1
(en)
|
2022-07-27 |
2025-03-13 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
CN116162160B
(zh)
*
|
2022-08-05 |
2025-07-29 |
南京融捷康生物科技有限公司 |
一种抗il-6的单域抗体及其用途
|
|
EP4577578A1
(en)
|
2022-08-22 |
2025-07-02 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
EP4594348A1
(en)
|
2022-09-27 |
2025-08-06 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
TW202430561A
(zh)
|
2022-09-30 |
2024-08-01 |
法商賽諾菲公司 |
抗cd28抗體
|
|
EP4605077A1
(en)
|
2022-10-18 |
2025-08-27 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
KR20250094703A
(ko)
|
2022-10-25 |
2025-06-25 |
아블린쓰 엔.브이. |
향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
|
|
EP4615842A1
(en)
|
2022-11-09 |
2025-09-17 |
Merck Patent GmbH |
Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
AR131441A1
(es)
|
2022-12-21 |
2025-03-19 |
Genzyme Corp |
Proteínas de unión anti-pd-1 ´ 4-1bb
|
|
AR131494A1
(es)
|
2022-12-23 |
2025-03-26 |
Ablynx Nv |
Vehículos de conjugación a base de proteína
|
|
CN120529914A
(zh)
|
2023-01-09 |
2025-08-22 |
奥德赛治疗股份有限公司 |
抗tnfr2抗原结合蛋白及其用途
|
|
EP4655324A1
(en)
|
2023-01-27 |
2025-12-03 |
Vib Vzw |
Cd163-binding conjugates
|
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
|
CN121013866A
(zh)
|
2023-02-10 |
2025-11-25 |
阿穆尼克斯制药公司 |
靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
|
|
IL322519A
(en)
|
2023-02-17 |
2025-10-01 |
Ablynx Nv |
Polypeptides that bind to the neonatal fc receptor
|
|
WO2024175787A1
(en)
|
2023-02-24 |
2024-08-29 |
Vrije Universiteit Brussel |
Anti-inflammatory pannexin 1 channel inhibitors
|
|
AR132121A1
(es)
|
2023-03-14 |
2025-05-28 |
Odyssey Therapeutics Inc |
Proteínas de unión a antígeno anti-cd25 y usos de las mismas
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
CN121013863A
(zh)
|
2023-03-31 |
2025-11-25 |
艾菲赛尔治疗株式会社 |
Tnfr2结合多肽及使用方法
|
|
WO2024208816A1
(en)
|
2023-04-03 |
2024-10-10 |
Vib Vzw |
Blood-brain barrier crossing antibodies
|
|
WO2024226410A1
(en)
|
2023-04-24 |
2024-10-31 |
Merck Sharp & Dohme Llc |
Trop2 binders and conjugates thereof
|
|
TW202509060A
(zh)
|
2023-05-08 |
2025-03-01 |
法商賽諾菲公司 |
免疫球蛋白單可變結構域的醣基化
|
|
WO2024231348A1
(en)
|
2023-05-11 |
2024-11-14 |
Vib Vzw |
Slc4a4/nbce1 inhibitors
|
|
AR132699A1
(es)
|
2023-05-17 |
2025-07-23 |
Odyssey Therapeutics Inc |
Anticuerpos de dominio único modificados
|
|
CN121311939A
(zh)
|
2023-06-05 |
2026-01-09 |
赛诺菲 |
使用机器学习模型预测免疫球蛋白单可变结构域的热稳定性
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
WO2024261338A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting pd-l1
|
|
WO2024261344A1
(en)
|
2023-06-23 |
2024-12-26 |
Vib Vzw |
Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
|
|
AR133108A1
(es)
|
2023-06-29 |
2025-08-27 |
Odyssey Therapeutics Inc |
Proteínas de unión a antígeno anti-trailr2 y sus usos
|
|
AR133188A1
(es)
|
2023-07-05 |
2025-09-03 |
Ablynx Nv |
ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
|
|
US20250051434A1
(en)
|
2023-08-11 |
2025-02-13 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
WO2025041077A1
(en)
|
2023-08-23 |
2025-02-27 |
Sanofi |
Ctla-4-based lysosomal degraders and uses thereof
|
|
TW202525843A
(zh)
|
2023-09-04 |
2025-07-01 |
法商賽諾菲公司 |
用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
|
|
WO2025061919A1
(en)
|
2023-09-22 |
2025-03-27 |
Ablynx Nv |
Bi- and multivalent albumin binders
|
|
TW202530265A
(zh)
|
2023-10-13 |
2025-08-01 |
美商奧迪希治療公司 |
抗cdh17抗原結合蛋白及其用途
|
|
WO2025088546A1
(en)
|
2023-10-25 |
2025-05-01 |
Ablynx N.V. |
Fc domain variants with enhanced fc receptor binding
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
WO2025109176A1
(en)
|
2023-11-22 |
2025-05-30 |
Exevir Bio Bv |
Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
|
|
WO2025114555A1
(en)
|
2023-11-30 |
2025-06-05 |
Oncospear Aps |
Anti-cd163 antibodies with improved adcc capabilities
|
|
TW202540188A
(zh)
|
2023-12-01 |
2025-10-16 |
比利時商艾伯霖克斯公司 |
精準活化的多肽
|
|
WO2025125577A1
(en)
|
2023-12-14 |
2025-06-19 |
Vib Vzw |
Antibodies against influenza b virus
|
|
WO2025133253A2
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based conjugation carriers for intranuclear delivery
|
|
WO2025133166A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based carriers for site-specific amine conjugation
|
|
WO2025133252A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting ceacam5
|
|
WO2025154058A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025154056A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect cda nanobodies and uses thereof
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025181155A1
(en)
|
2024-02-26 |
2025-09-04 |
Vib Vzw |
Human beta-glucocerebrosidase binders and uses thereof
|
|
GB202403780D0
(en)
|
2024-03-15 |
2024-05-01 |
Avacta Life Sciences Ltd |
Polypeptides and methods for detecting and quantifying small molecules
|
|
WO2025196308A1
(en)
|
2024-03-22 |
2025-09-25 |
Vib Vzw |
Means and methods for displaying fc-containing proteins on cells and selection thereof
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025219231A1
(en)
|
2024-04-15 |
2025-10-23 |
Vib Vzw |
Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
|
|
WO2025229159A1
(en)
|
2024-05-01 |
2025-11-06 |
Commit Biologics Aps |
Antibodies and antibody constructs against cd20
|
|
WO2025238157A1
(en)
|
2024-05-15 |
2025-11-20 |
Katholieke Universiteit Leuven |
Multispecific binding agent suitable for use in cancer immune therapy
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2025257408A1
(en)
|
2024-06-14 |
2025-12-18 |
Sanofi |
Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
|
|
WO2025262150A2
(en)
|
2024-06-18 |
2025-12-26 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|